GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: KI-CDK9d-32 is a CDK9-directed PROTAC [2]. CDK9 binding is achieved by inclusion of the inhibitor KI-ARv-03 [1] (the inhibitor that was modified to become istisociclib), and pomalidomide is used as the cereblon (CRBN) ubiquitin ligase recruiting moiety. CDK9 degradation downregulates MYC protein expression and destabilizes nucleolar homeostasis.
|
|
References |
1. Richters A, Doyle SK, Freeman DB, Lee C, Leifer BS, Jagannathan S, Kabinger F, Koren JV, Struntz NB, Urgiles J et al.. (2021)
Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. Cell Chem Biol, 28 (2): 134-147.e14. [PMID:33086052] |
2. Toure MA, Motoyama K, Xiang Y, Urgiles J, Kabinger F, Koglin AS, Iyer RS, Gagnon K, Kumar A, Ojeda S et al.. (2025)
Targeted degradation of CDK9 potently disrupts the MYC-regulated network. Cell Chem Biol, 32 (4): 542-555.e10. [PMID:40154489] |